CHRU De Nancy
- Address
- Rue Du Morvan, 54500 Vandoeuvre Les Nancy, France
Cardiovascular Diseases
The department conducts studies on cardiovascular health, aiming to test new therapies and improve patient outcomes.
- Acute Coronary Syndrome
- Acute myocardial infarction
- Chronic Heart Failure With Reduced Ejection Fraction
- Uncontrolled Hypertension in chronic kidney disease
- Pulmonary Arterial Hypertension
Ongoing trials evaluate novel anticoagulants, blood‑pressure optimization strategies, and agents that reduce cardiovascular events and heart‑failure hospitalizations.
Digestive System Diseases & Neoplasms
Research focuses on gastro‑intestinal and liver cancers, exploring innovative treatment combinations to extend survival.
- Hepatocellular Carcinoma
- Advanced Hepatocellular Carcinoma
- Biliary tract carcinoma
- Colon carcinoma
- Small bowel adenocarcinoma
Studies assess immunotherapy, targeted agents, and neo‑adjuvant chemotherapy protocols to improve disease‑free survival.
Immune System Diseases
Trials address immune‑mediated and autoimmune disorders, seeking safer, more effective therapeutic options.
- Ulcerative Colitis
- Crohn's disease
- Food allergy
- Non‑infectious uveitis
- Binge eating disorder
Research evaluates biologics, oral small‑molecule agents, and dietary interventions to control inflammation and improve quality of life.
Hemic and Lymphatic Diseases
The site investigates blood‑related cancers and bone‑marrow failures, aiming to raise remission rates and long‑term survival.
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Diffuse Large B‑Cell Lymphoma
- Follicular lymphoma
- Marginal Zone Lymphoma
Studies compare novel kinase inhibitors, bispecific antibodies, and reduced‑intensity conditioning regimens for stem‑cell transplantation.
Nutritional and Metabolic Diseases
Clinical work targets metabolic liver disease and related metabolic disorders, testing agents that reverse tissue damage.
- Non‑Alcoholic Steatohepatitis (NASH)
- Metabolic Dysfunction‑Associated Steatohepatitis (MASH)
- Fibrosis
- Diabetes‑related complications
Trials assess drugs that improve liver histology, reduce fibrosis, and enhance overall metabolic health.
Respiratory Tract Diseases
Studies aim to improve outcomes for lung‑related conditions, including rare progressive diseases.
- Interstitial lung disease
- Pulmonary arterial hypertension
- Acute respiratory complications
Investigations include targeted therapies and functional measures such as exercise capacity to assess efficacy.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 31 therapeutic areas and 15 of 640 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 576 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 118 by active trials.
lock +117 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +71 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHRU De Nancy
lock Showing 1 of 527 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) | Acadia Pharmaceuticals Inc. | Phase III | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 640 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 38 | Unknown | 2014-03-24 | 2026-06-15 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.